Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Joe Wesley who wrote (2430)	1/12/1999 11:44:00 AM
From: jopawa	Read Replies (1) \| Respond to of 4676

Market seems to think so also, up on a brutal day. John

To: Joe Wesley who wrote (2430)	1/15/1999 11:49:00 PM
From: tommysdad	Respond to of 4676

Better read that release again. I don't see that ABT is planning on developing antisense drugs. Rather, they are using ISIS's experience in antisense to determine the targets and their utility. In fact, it sounds like ABT is actually prohibited from developing antisense drugs as part of this collaboration. If they thought "antisense works", do you think they would sign such an agreement? Unlikely. This press release says: "ABT thinks antisense can be used as drug discovery tool, but is willing to allow ISIS to keep all the antisense drugs they think they can develop". Big difference. The royalties on this cannot be large. The big money is in the molecules, not in how to find them. It's a nice little agreement, but ISIS is not going to pull down big bucks from it . . .